1.A Large Hematoma Due to Benign Ulcer Perforation of the Gastric Fundus Resembling Submucosal Tumor.
Nam Yong KIM ; Jung Hwan OH ; Soo Jin CHOI ; Seung Kyoung KIM ; Youn Mi SONG ; Byung Soo JIE ; Seung Hyun OH ; Sang Wook CHOI
Korean Journal of Gastrointestinal Endoscopy 2010;41(3):159-162
The gastric fundus is a rare site for benign ulcer and perforation to occur. A 47 year-old male presented to the emergency department with epigastric pain. An endoscopic examination revealed a submucosal tumor-like lesion with friable, superficial ulceration in the high body of the stomach. We performed surgical resection to rule out malignancy because of the lesion's large size and we found chronic gastric ulcer perforation, which was pathologically diagnosed. We presumed that the formation of the large hematoma, which mimicked a submucosal tumor, was a result of repeated bleeding, perforation and healing. We report here on a case of a large hematoma due to a benign gastric ulcer perforation in the fundus, and this all mimicked a submucosal tumor.
Emergencies
;
Gastric Fundus
;
Hematoma
;
Hemorrhage
;
Humans
;
Male
;
Peptic Ulcer Perforation
;
Stomach
;
Stomach Ulcer
;
Ulcer
2.Alteration of Nitric Oxide Synthase Subtype Expression in Contralateral Testis of Rat in Response to Unilateral Testicular Torsion Followed by Detorsion.
Seung June OH ; Chang Shin PARK ; Kyung Hoon LEE ; Dae Joong KIM ; Dea Jung LIM ; Jin Ren JIE ; Ahn Ki LEE ; Hwang CHOI
Korean Journal of Urology 2000;41(5):650-658
No abstract available.
Animals
;
Nitric Oxide Synthase*
;
Nitric Oxide*
;
Rats*
;
Spermatic Cord Torsion*
;
Testis*
3.Angiographic spontaneous pseudo-resolution of a coronary artery aneurysm after implantation of a sirolimus-eluting stent.
Yong Woo CHOI ; Hong Seok LIM ; Seung Jea TAHK ; Myeong Ho YOON ; Hyoung Mo YANG ; Xiong Jie JIN
The Korean Journal of Internal Medicine 2016;31(5):987-990
No abstract available.
Aneurysm*
;
Coronary Aneurysm
;
Coronary Vessels*
;
Drug-Eluting Stents
;
Stents*
;
Ultrasonography, Interventional
4.The Impact of Esophageal Reflux-Induced Symptoms on Quality of Life after Gastrectomy in Patients with Gastric Cancer.
Min Hye IM ; Jong Won KIM ; Whan Sik KIM ; Jie Hyun KIM ; Young Hoon YOUN ; Hyojin PARK ; Seung Ho CHOI
Journal of Gastric Cancer 2014;14(1):15-22
PURPOSE: To evaluate the prevalence of esophageal reflux-induced symptoms after gastrectomy owing to gastric cancer and assess the relationship between esophageal reflux-induced symptoms and quality of life. MATERIALS AND METHODS: From January 2012 to May 2012, 332 patients were enrolled in this cross-sectional study. The patients had a history of curative resection for gastric cancer at least 6 months previously without recurrence, other malignancy, or ongoing chemotherapy. Esophageal reflux-induced symptoms were evaluated with the GerdQ questionnaire. The quality of life was evaluated with the European Organization for Research and Treatment QLQ-C30 and STO22 questionnaires. RESULTS: Of the 332 patients, 275 had undergone subtotal gastrectomy and 57 had undergone total gastrectomy. The number of GerdQ(+) patients was 58 (21.1%) after subtotal gastrectomy, and 7 (12.3%) after total gastrectomy (P=0.127). GerdQ(+) patients showed significantly worse scores compared to those for GerdQ(-) patients in nearly all functional and symptom QLQ-C30 scales, with the difference in the mean score of global health status/quality of life and diarrhea symptoms being higher than in the minimal important difference. Additionally, in the QLQ STO22, GerdQ(+) patients had significantly worse scores in every symptom scale. The GerdQ score was negatively correlated with the global quality of life score (r=-0.170, P=0.002). CONCLUSIONS: Esophageal reflux-induced symptoms may develop at a similar rate or more frequently after subtotal gastrectomy compared to that after total gastrectomy, and decrease quality of life in gastric cancer patients. To improve quality of life after gastrectomy, new strategies are required to prevent or reduce esophageal reflux.
Cross-Sectional Studies
;
Diarrhea
;
Drug Therapy
;
Gastrectomy*
;
Gastroesophageal Reflux
;
Humans
;
Prevalence
;
Quality of Life*
;
Recurrence
;
Stomach Neoplasms*
;
Weights and Measures
;
Surveys and Questionnaires
5.The Korean Version of the Barkley Deficits in Executive Functioning Scale: Clinical Utility in Adult Attention-Deficit/Hyperactivity Disorder
Jie-seung CHOI ; Wonhye LEE ; Ho-won AHN ; Ji-Hae KIM ; Yoo-Sook JOUNG ; Keun hee LEE ; Jong-Il LEE
Journal of Korean Neuropsychiatric Association 2020;59(2):136-141
Objectives:
To identify the clinical utility of the Korean version of the Barkley Deficits in Executive Functioning Scale (K-BDEFS) assessing executive functioning.
Methods:
The patient group included 144 adult attention-deficit/hyperactivity disorder (ADHD) patients visiting the Adult ADHD Outpatient Clinic of the National Center for Mental Health. Adult ADHD Self-Report Scale version 1.1, Mini International Neuropsychiatric Interview, and K-BDEFS were used. The control subjects were 144 age, sex, and education-matched general adults who participated in the study of the validity of the K-BDEFS in Samsung Medical Center.
Results:
An analysis of the mean total K-BDEFS score, executive functioning symptom count, and ADHD-executive function (EF) index score revealed a significant difference between the adult ADHD and control group (p<0.05). Five subscales of the K-BDEFS, which assess the specific domains of the executive function, revealed a significant difference between the ADHD group and control group (p<0.05). The area under curve (AUC) of the K-BDEFS total score, the EF symptom count, and the ADHD-EF index were 0.943, 0.949, and 0.908, respectively, in the analysis using the receiver operating characteristic curve. All AUC values were over 0.90. Therefore, KBDEFS is a reliable and valid screening instrument for diagnosing adult ADHD. In an assessment of the sensitivity and specificity of the cutoff scores, a cutoff of 183.5 points for the K-BDEFS total score, 26.5 points for the EF symptom count, and 23.5 points for the ADHD-EF index showed a reliable sensitivity and specificity above 80%.
Conclusion
To the best of the authors’ knowledge, this is the first study to examine the predictive validity and clinical utility of K-BDEFS in adult ADHD. The results suggest that the K-BDEFS could be used as a valid and reliable tool for the diagnosis and clinical intervention of adult ADHD.
6.Growth Patterns of Signet Ring Cell Carcinoma of the Stomach for Endoscopic Resection.
Hyunki KIM ; Jie Hyun KIM ; Yong Chan LEE ; Hoguen KIM ; Young Hoon YOUN ; Hyojin PARK ; Seung Ho CHOI ; Sung Hoon NOH ; Takuji GOTODA
Gut and Liver 2015;9(6):720-726
BACKGROUND/AIMS: It is difficult to precisely detect the lateral margin during endoscopic submucosal dissection (ESD) for signet ring cell carcinoma (SRC) because SRC often expands to lateral direction through the lamina propria. Thus, the aim of this study was to classify the intramucosal spreading patterns of SRC and to analyze the patients' clinicopathological findings according to the spreading patterns. METHODS: The intramucosal spreading patterns of SRC were classified as expansive or infiltrative types. A total of 100 surgical and 42 ESD specimens were reviewed. RESULTS: In the surgical specimens, the proportions of expansive and infiltrative types were 44% and 56%, respectively. The infiltrative type was more commonly associated with old age, atrophy, and intestinal metaplasia in surrounding mucosa and the absence of Helicobacter pylori compared with the expansive type. In ESD specimens, the proportions of expansive and infiltrative types were each 50%. When lateral margin-positive lesions were compared with -negative lesions, larger size, residual lesion, and the lack of a neutrophil infiltration were more significantly associated with lateral margin-positive lesions. All cases with residual tumors in lateral margin-positive lesions were classified as the infiltrative type. CONCLUSIONS: SRC surrounded with atrophy and/or intestinal metaplasia often spreads subepithelially in the margin. This finding may suggest that a larger safety margin is necessary in this type during ESD.
Adult
;
Carcinoma, Signet Ring Cell/*pathology/*surgery
;
Dissection/*methods
;
Female
;
Gastric Mucosa/pathology
;
*Gastroscopy
;
Humans
;
Intestines/pathology
;
Male
;
Metaplasia/pathology
;
Middle Aged
;
Neoplasm Invasiveness
;
Retrospective Studies
;
Stomach/pathology
;
Stomach Neoplasms/*pathology/*surgery
7.Clinicopathologic Features of Submucosal Papillary Gastric Cancer Differ from Those of Other Differentiated-Type Histologies
Seung Yong SHIN ; Jie-Hyun KIM ; Myeong-Cherl KOOK ; Do Youn PARK ; Keun Won RYU ; Il Ju CHOI ; Sung Hoon NOH ; Hyunki KIM ; Yong Chan LEE
Gut and Liver 2021;15(1):44-52
Background/Aims:
Papillary gastric cancer (GC) is classified as differentiated adenocarcinoma, together with well-differentiated (WD) and moderately differentiated (MD) adenocarcinoma. This study evaluated the risk of lymph node metastasis (LNM) in submucosal (SM) invasive papillary GC compared with other differentiated early GC types.
Methods:
This retrospective study involved three tertiary hospitals and enrolled 1,798 lesions with differentiated SM invasive GC treated with curative gastrectomy between March 2001 and December 2012. All pathology slides were reviewed, and clinicopathologic findings associated with LNM, including tumor size, location, gross type, ulceration, depth and width of SM invasion, and lymphovascular invasion (LVI), were analyzed.
Results:
The proportion of SM papillary GC was 2.8% (n=51). SM papillary GC was associated with larger tumor size and deeper and wider SM invasion than other differentiated GC types.LNM was significantly higher in the papillary type than in the MD and WD types. LNM was found in 27.5% of SM papillary GC patients (WD: 9.0%, MD: 21.2%). LVI was the only significant risk factor for LNM in SM papillary GC. The depth or width of SM invasion was not associated with LNM in papillary GC. Lower third location or elevated gross appearance was significantly associated with LVI.
Conclusions
SM papillary GC had the highest LNM rate, with features different from those of other differentiated SM invasive GCs. The treatment strategy for SM papillary GC should be carefully approached, especially for lesions located in the lower third or of the elevated gross type.
8.Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition
Hye-Kyung JUNG ; Seung Joo KANG ; Yong Chan LEE ; Hyo-Joon YANG ; Seon-Young PARK ; Cheol Min SHIN ; Sung Eun KIM ; Hyun Chul LIM ; Jie-Hyun KIM ; Su Youn NAM ; Woon Geon SHIN ; Jae Myung PARK ; Il Ju CHOI ; Jae Gyu KIM ; Miyoung CHOI ;
Korean Journal of Medicine 2021;96(3):160-189
Helicobacter pylori (H. pylori) infection is one of the most common infectious diseases worldwide. Although its incidence is gradually decreasing, about half of the world's population still get infected. H. pylori infection is responsible for substantial gastrointestinal morbidity worldwide. It is the most common cause of gastric and duodenal ulcers as well as gastric cancer. Since the revision of the H. pylori Clinical Practice Guidelines in 2013, the eradication rate of H. pylori has gradually decreased with the use of classical triple therapy, wherein amoxicillin, clarithromycin, and proton pump inhibitors are administered, for 7 days. According to a nationwide randomized controlled study conducted by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was due to increased antimicrobial resistance induced by the use of antibiotics, especially clarithromycin. The update of clinical practice guideline for treatment of H. pylori was developed based on evidence-based medicine by conducting a meta-analysis. The draft recommendations were finalized after expert consensus on three recommendations regarding the indication for treatment and eight recommendations on the treatment itself. These guidelines are designed to provide patients, nurses, medical school students, policymakers, and clinicians with clinical evidence to guide primary care and treatment of H. pylori infection. These may differ from current medical insurance standards and will be revised further, if necessary, based on research-based evidence.
9.Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition
Hye-Kyung JUNG ; Seung Joo KANG ; Yong Chan LEE ; Hyo-Joon YANG ; Seon-Young PARK ; Cheol Min SHIN ; Sung Eun KIM ; Hyun Chul LIM ; Jie-Hyun KIM ; Su Youn NAM ; Woon Geon SHIN ; Jae Myung PARK ; Il Ju CHOI ; Jae Gyu KIM ; Miyoung CHOI ;
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020;20(4):261-287
Helicobacter pylori (H. pylori) infection is one of the most common infectious diseases worldwide. Although its incidence is gradually decreasing, about half of the world's population still get infected. H. pylori infection is responsible for substantial gastrointestinal morbidity worldwide. It is the most common cause of gastric and duodenal ulcers as well as gastric cancer. Since the revision of the H. pylori Clinical Practice Guidelines in 2013, the eradication rate of H. pylori has gradually decreased with the use of classical triple therapy, wherein amoxicillin, clarithromycin, and proton pump inhibitors are administered, for 7 days. According to a nationwide randomized controlled study conducted by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was due to increased antimicrobial resistance induced by the use of antibiotics, especially clarithromycin. The update of clinical practice guideline for treatment of H. pylori was developed based on evidence-based medicine by conducting a meta-analysis. The draft recommendations were finalized after expert consensus on three recommendations regarding the indication for treatment and eight recommendations on the treatment itself. These guidelines are designed to provide patients, nurses, medical school students, policymakers, and clinicians with clinical evidence to guide primary care and treatment of H. pylori infection. These may differ from current medical insurance standards and will be revised further, if necessary, based on research-based evidence.
10.Eradication Rates of Clarithromycin Triple Therapy in Korea: A Systematic Review and Meta-analysis
Seung Joo KANG ; Hye-Kyung JUNG ; Yong Chan LEE ; Hyo-Joon YANG ; Seon-Young PARK ; Cheol Min SHIN ; Sung Eun KIM ; Hyun Chul LIM ; Jie-Hyun KIM ; Su Youn NAM ; Woon Geon SHIN ; Jae Myung PARK ; Il Ju CHOI ; Jae Gyu KIM ; Miyoung CHOI ;
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021;21(1):35-47
Background/Aims:
Standard triple therapy, including a proton pump inhibitor, clarithromycin, and amoxicillin, has been recommended as the first-line for Helicobacter pylori infection. However, the eradication rate of standard triple therapy has declined over the past years because of the increasing resistance to clarithromycin in Korea. We analyzed the eradication rates and the 10-year change in the eradication rates in Korea.
Methods:
PubMed, EMBASE, the Cochrane Library, and KoreaMed were searched for studies published between January 2007 and June 2018. The pooled eradication rates and their 95% CIs were estimated using a random-effect logistic regression model.
Results:
Twenty-six randomized controlled studies on standard triple therapy conducted in Korea were selected. The intention-to-treat (ITT) and per protocol analyses showed pooled eradication rates of standard triple therapy of 71.6% (95% CI, 69.9~73.3%) and 79.6% (95% CI, 76.6~82.2%), respectively. The eradication rate decreased with time. The ITT analysis showed that the 14-day therapy (78.1% [95% CI, 75.2~80.7%]) had significantly higher eradication rates than the 7-day therapy (70.0% [95% CI, 68.5~71.4%]) (P<0.01).
Conclusions
These results suggest that the eradication rate of standard triple therapy, as the first-line therapy, has shown an unacceptable decrease. The eradication rate increased when the duration of therapy was increased to 14 days, but it was not satisfactory. Therefore, other treatment regimens or therapies based on susceptibility tests should be considered for the first-line therapy.